Fresenius Kabi Takes Control Of mAbxience To Bolster Biosimilars
Also Announces Acquisition Of Ivenix To Strengthen Medtech Business
Fresenius Kabi has made a major move to bolster its biosimilars business by acquiring a majority 55% stake in mAbxience, with the purchase price comprising €495m upfront as well as subsequent milestone payments. The deal offers Fresenius not only enhanced biosimilars capabilities but also access to the expanding biologics CDMO market.
